Abstract 1053P
Background
ICIs used across multiple disease sites including both early and advanced stage cancers. Systemic inflammatory markers including neutrophil to lymphocyte ratios (NLR), platelet to lymphocyte ratios (PLR) and lymphocyte to monocyte ratios (LMR) has been found to be prognostic across different tumor types, but less is known about their prognostic role in patients receiving ICIs. Here we used population-level administrative data to evaluate the potential association between NLR, PLR and LMR and overall survival (OS) among patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of patients with solid tumors initiating ICI therapy in Ontario, Canada from June 2012 to October 2018 and obtained information on baseline demographics, clinical covariates, inflammatory markers (NLR, PLR, LMR) at the start of ICI, and overall survival (OS). We applied multivariable Cox proportional hazard models to evaluate the impact of NLR, PLR, and LMR on OS, adjusting for sex, age, cancer center, autoimmune history, recent hospitalization and comorbidity score.
Results
Among 4683 patients, median age was 67, 57% male; 46% had lung cancer, 35% melanoma, 9% renal cancers; 40% received nivolumab, 36% pembrolizumab, 17% ipilimumab. Median OS was 317 days. Using previous cutoffs in the literature, 44% of patients had a high NLR (≥ 5), 58% high PLR (≥ 200), and 60% high LMR (≥ 1.5). Among all patients, those with high NLR (aHR=1.80, 95% CI [1.65-1.97] p
Conclusions
Among cancer patients receiving ICIs, higher NLR and PLR and lower LMR were prognostic of OS across cancer types. Further studies validating their prognostic role in ICI therapy is warranted.
Legal entity responsible for the study
The authors.
Funding
ASCO / Conquer Cancer Foundation - Young Investigator Award.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03
911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Presenter: Xinrui Chen
Session: Poster session 03
912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Presenter: Ramin Ajami
Session: Poster session 03
913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Presenter: Juan Carlos Redondo González
Session: Poster session 03
914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Presenter: Juan Carlos Redondo González
Session: Poster session 03
915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Simon Laban
Session: Poster session 03
916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Presenter: Abhishek Aggarwal
Session: Poster session 03